Literature DB >> 22312622

Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations.

Eli O Meltzer1, Gary N Gross, Rohit Katial, William W Storms.   

Abstract

People with allergic rhinitis rate their overall health significantly lower than individuals without nasal allergies. Compared with the general population, more people with AR complain of difficulty getting to sleep, waking up during the night, lack of a good night's sleep, or a combination of these, as a result of their nasal symptoms. More than half of individuals with AR describe their symptoms as impacting daily life a lot or to a moderate degree. More adults with AR report that their health limits them from doing well at work compared with adults without nasal allergies, and their estimated productivity drops by an average of 20% on days when their nasal symptoms are at their worst.

Entities:  

Mesh:

Year:  2012        PMID: 22312622

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  16 in total

1.  Polysomnographic findings in persistent allergic rhinitis.

Authors:  Bulent Bozkurt; K Serife Ugur; Harun Karamanli; Fatma Kucuker; Duygu Ozol
Journal:  Sleep Breath       Date:  2016-08-01       Impact factor: 2.816

2.  Impact of nasal obstruction on sleep quality: a community-based study of women.

Authors:  Caroline Bengtsson; Lars Jonsson; Mats Holmström; Malin Svensson; Jenny Theorell-Haglöw; Eva Lindberg
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-05       Impact factor: 2.503

3.  Does the duration and time of sleep increase the risk of allergic rhinitis? Results of the 6-year nationwide Korea youth risk behavior web-based survey.

Authors:  Jeoung A Kwon; Minjee Lee; Ki-Bong Yoo; Eun-Cheol Park
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

4.  Is health-related quality of life associated with upper and lower airway inflammation in asthmatics?

Authors:  Nicola Scichilone; Fulvio Braido; Salvatore Taormina; Elena Pozzecco; Alessandra Paternò; Ilaria Baiardini; Vincenzo Casolaro; Giorgio Walter Canonica; Vincenzo Bellia
Journal:  Biomed Res Int       Date:  2013-08-31       Impact factor: 3.411

5.  The international survey on the management of allergic rhinitis by physicians and patients (ISMAR).

Authors:  Carlos E Baena-Cagnani; Giorgio W Canonica; Mohamed Zaky Helal; René Maximiliano Gómez; Enrico Compalati; Mario E Zernotti; Mario Sanchez-Borges; Fabio F Morato Castro; Margarita Murrieta Aguttes; Aida López-Garcia; Faheem A Tadros
Journal:  World Allergy Organ J       Date:  2015-03-20       Impact factor: 4.084

6.  Survey on the prevalence of allergic rhinitis and its effect on the quality of high school students' life.

Authors:  Maryam Amizadeh; Hossein Safizadeh; Nasrin Bazargan; Zahra Farrokhdoost
Journal:  Iran J Otorhinolaryngol       Date:  2013

7.  The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey.

Authors:  David Price; Glenis Scadding; Dermot Ryan; Claus Bachert; G Walter Canonica; Joaquim Mullol; Ludger Klimek; Richard Pitman; Sarah Acaster; Ruth Murray; Jean Bousquet
Journal:  Clin Transl Allergy       Date:  2015-11-18       Impact factor: 5.871

8.  Reduced work/academic performance and quality of life in patients with allergic rhinitis and impact of allergen immunotherapy.

Authors:  A Roger; E Arcalá Campillo; M C Torres; C Millan; I Jáuregui; E Mohedano; S Liñan; P Verdu; N Rubira; M Santaolalla; P González; A Orovitg; E Villarrubia
Journal:  Allergy Asthma Clin Immunol       Date:  2016-08-11       Impact factor: 3.406

9.  UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study.

Authors:  David B Price; Glenis Scadding; Claus Bachert; Hesham Saleh; Shuaib Nasser; Victoria Carter; Julie von Ziegenweidt; Alice M S Durieux; Dermot Ryan
Journal:  NPJ Prim Care Respir Med       Date:  2016-06-23       Impact factor: 2.871

Review 10.  A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US.

Authors:  Bruce M Prenner
Journal:  J Asthma Allergy       Date:  2016-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.